News
11-07-2010, 10:32 PM
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented positive preliminary data from fully monitored study data for the entire study population of 80 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma.
More... (http://www.news-medical.net/news/20101108/Provectus-presents-PV-10-Phase-2-clinical-trial-data-for-metastatic-melanoma-at-Sydney-Congress.aspx)
More... (http://www.news-medical.net/news/20101108/Provectus-presents-PV-10-Phase-2-clinical-trial-data-for-metastatic-melanoma-at-Sydney-Congress.aspx)